The aim of the present study was to determine the effects of pretreatment with probiotics on brain injury, neurological function, and pro-inflammatory cytokine of TNF-[alpha], and MDA content, as an oxidative stress biomarker, in a transient model of focal cerebral ischemia
Pulmonary arteriovenous malformations: cerebral ischemia
and neurologic manifestations.
Transient global cerebral ischemia
(TGCI) is caused by a temporary deficiency of cerebral blood supply and leads to selective neuronal death in specific brain areas.
Cerebral hyperperfusion after carotid endarterectomy is associated with preoperative hemodynamic impairment and intraoperative cerebral ischemia
The main scope of this article is to use the methodology of Gaussian mixed models (GMM) to model the response variable latency (lat - time taken by the animal to find the real hiding place) of a pharmacological experiment that aims at evaluating the effect of fish oil (FO) to the treatment on animals submitted to cerebral ischemia
, checking if treated animals showed improvement in their clinical condition (amnesia) in relation to the animals that were not treated with FO.
2007) demonstrated neuroprotective activity of p-tyrosol in the model of focal cerebral ischemia
with intraperitoneal introduction of this substance in doses of 10 and 30mg/kg.
The related experiments had proved that NBP had the pharmacological effects of reconstructing the microcirculation, reducing the infarcted lesions after focal cerebral ischemia
, and reducing the degrees of neurological injuries, although the exact mechanism was still unclear.
Resveratrol protects neurons and the myocardium by reducing oxidative stress and ameliorating mitochondria damage in a cerebral ischemia
Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia
The presented data show that moderate doses of STVNA (5, 10, and 20 mg/kg) have a protective effect against neuronal damage induced by cerebral ischemia
and that this protection is associated with an improvement in neurological functions.
Worldwide, cerebral ischemia
is one of the leading causes of long-term disability, morbidity, and death [1, 2].
The advent of HMCoA reductase inhibitors (Statins), has contributed new evidence supporting association of total cholesterol and LDL levels with risk of Cerebral Ischemia
with no modification of risk for hemorrhagic stroke.
They include local symptoms and signs such as head and/ or neck pain (the two most frequent initial symptoms), Horner's syndrome (approximately in 25% of cases), retinal artery occlusion, tinnitus, audible bruit, cranial neuropathies, scalp tenderness, orbital or monocular pain (rare in carotid artery dissections), cervical nerve root involvement (rare in vertebral artery dissection), or more generalized presentations such as cerebral ischemia
and infarctions and in the case of vertebral artery dissection, lateral medullary infarction (Wallenberg's syndrome) and other posterior circulation territory infarctions and spinal cord ischemia.
The risk of causing hemorrhage into an ischemic area or rupturing an aneurysm must be weighed against the benefits of improving perfusion, but augmentation of blood pressure in the face of acute cerebral ischemia
to promote collateral blood supply is probably protective in most settings.
5% of all acute cerebral ischemia
and infarcts with risk factors including smoking, estrogen-containing birth control use, coagulopathy, neoplasm, and congenital malformation.